Borneol is a bicyclic monoterpene alcohol found across multiple AromaForge oils, including rosemary, lavandin, spike lavender, oregano compactum, lanyana, and true borneol-type thyme chemotypes. Its public evidence base is broader than many archive constituents, but it is still dominated by preclinical and formulation literature rather than standalone human aroma-use outcomes. The strongest direct themes are permeability-enhancing behavior across biological barriers, animal anti-inflammatory and antinociceptive findings, and transport-focused review literature that should not be translated into medical claims.
Chemical identity and composition
NIST lists borneol under CAS 507-70-0 with formula C10H18O and notes that the same structure category includes stereoisomers such as (+)-borneol and epi-borneol. PubChem resolves generic Borneol to CID 64685 with the bicyclic bornane alcohol skeleton 1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol. In the archive, borneol appears both as a supporting constituent in rosemary and lavandin profiles and as a dominant chemotype marker in thyme red borneol type, where current local oil data place it near 30%.
Aroma and practical use
- Use the recorded camphoraceous, minty, woody, herbal, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2013 mouse study reported that borneol reduced writhing and formalin-associated nociceptive behavior, lowered carrageenan-induced leukocyte migration, and did not impair motor coordination.
The Europe PMC abstract describes significant central and peripheral antinociceptive effects plus anti-inflammatory activity in mice.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2013 rabbit cornea study found that 0.2% borneol increased permeability for several model compounds, with the strongest effect reported for 4 kDa FITC-dextran among the larger hydrophilic probes tested.
The abstract reports 1.82-fold and 2.49-fold increases for rhodamine B and sodium fluorescein, a 4.18-fold increase for 4 kDa FITC-dextran, and no toxic reaction signal at tested concentrations.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2019 systematic review of experimental ischemic-stroke studies concluded that borneol significantly decreased blood-brain barrier permeability and improved neurological outcomes in included animal models.
The review included fifteen studies involving 308 animals and summarized borneol's preclinical effects on Evans blue leakage, brain water content, infarct area, inflammation, oxidative reactions, apoptosis, and related pathways.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The strongest accessible borneol literature in this pass is preclinical or formulation-focused, so archive copy should avoid implying established clinical efficacy from those models.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because borneol can increase permeability across biological barriers, formulation context matters when it is combined with other active ingredients.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
No constituent-specific IFRA dermal limit or comparable public aroma-use restriction was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
ThymolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Thymol report →SpathulenolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · whole_oil
No source citation attached.
Read Spathulenol report →How the effects were investigated
temporary modulation of biological barrier permeability
Review and preclinical sources consistently describe borneol as increasing transport across biological barriers, especially in blood-brain and ocular-delivery models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
reduction of inflammatory signaling in preclinical models
The ischemic-stroke systematic review and animal nociception paper both describe anti-inflammatory effects, with the review summarizing links to oxidative stress, apoptosis, P-glycoprotein, and nitric-oxide-related pathways in experimental systems.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (8)
- No high-quality human trial on isolated borneol as a standalone aroma constituent was verified in this pass.
- Much of the recent literature concerns borneol as a delivery adjuvant or nanocarrier modifier rather than a simple essential-oil constituent used on its own.
- Public constituent-specific sensitization and topical-use-limit data were not clearly verified in the reviewed sources.
- Safety-verification pass (2026-07-11): a rabbit dermal-irritation study (borneol essential oil, PMC8810075) found no significant irritation at 25/50/70% concentrations (14-day chronic scoring) and only minimal transient erythema at 100%; this study did not test sensitization or phototoxicity, so it corroborates low irritation potential but does not establish a formal IFRA/Tisserand dermal-use-limit percentage. No IFRA standard for borneol was located; dermal_limit_pct remains unverified.
- No IFRA Standard or Tisserand & Young numeric dermal-use limit for isolated Borneol (CAS 507-70-0) was located in this additional pass, consistent with the prior 2026-07-11 finding recorded elsewhere in this file's gaps. The prior uncited dermal_limit_pct of 0.1 has been corrected to null rather than left as an unsupported figure.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.